Personal Profile
Dr Jurjees Hasan graduated in India following which, he moved to the UK to undertake his specialist training. He was appointed to the post of Medical Oncologist at The Christie NHS Foundation Trust during 2005.
Dr Jurjees Hasan's subspecialty interests include gynaecological malignancies, colorectal cancer and carcinoma of unknown primary site. Dr Jurjees Hasan is a lead medical oncologist for gynaecological malignancies and covers the southern sector of the Greater Manchester Cancer Network. He also supports Outreach chemotherapy at Stepping Hill Hospital where he has developed a chemotherapy service for colorectal cancers.
Dr Jurjees Hasan has served as Principle Investigator in Phase ll and Phase lll studies in gynaecoligical and colorectal cancer. He is actively involved in programmes to develop HIPEC with cytoreductive surgery for ovarian cancer, management of malignant bowel obstruction and molecular oncology to support personalised targeted therapies. Dr Jurjees Hasan's work has been published in peer reviewed journals and presented at international oncology meetings. He has served on various NICE panels and referees manuscripts for publication in oncology journals.
Dr Jurjees Hasan's subspecialty interests include gynaecological malignancies, colorectal cancer and carcinoma of unknown primary site. Dr Jurjees Hasan is a lead medical oncologist for gynaecological malignancies and covers the southern sector of the Greater Manchester Cancer Network. He also supports Outreach chemotherapy at Stepping Hill Hospital where he has developed a chemotherapy service for colorectal cancers.
Dr Jurjees Hasan has served as Principle Investigator in Phase ll and Phase lll studies in gynaecoligical and colorectal cancer. He is actively involved in programmes to develop HIPEC with cytoreductive surgery for ovarian cancer, management of malignant bowel obstruction and molecular oncology to support personalised targeted therapies. Dr Jurjees Hasan's work has been published in peer reviewed journals and presented at international oncology meetings. He has served on various NICE panels and referees manuscripts for publication in oncology journals.
